drugset / Trial / NCT06656962
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single-arm, open-label exploratory clinical study conducted in subjects with ANCA-associated nephritis (AAGN), aiming to evaluate the efficacy and safety of Telitacicept in the treatment of AAGN.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2025-12-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 0.75 g | Intravenous |
| Background | Methylprednisolone | Other / unclassified | 500 mg | — |
| Background | Prednisone | Other / unclassified | 1 mg/kg | — |